Genmab revenue and financials

GMAB · NASDAQ · USD

Secondary listing. The primary listing is Genmab · Nasdaq Copenhagen (DKK)

$37.80−1.77%−$0.68

Close · October 6, 2026

In the fiscal year ended December 2025, Genmab reported revenue of kr 3.72B (+19.19% year over year). Net income was kr 963M, a net margin of 25.9%.

Annual revenue · 2025: kr 3.72B
  1. kr 2.37B2017
  2. kr 3.03B2018
  3. kr 5.37B2019
  4. kr 2.39B2023
  5. kr 3.12B2024
  6. kr 3.72B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+19.19%
2025 vs 2024
Net income growth
−87.72%
2025 vs 2024
Net margin
25.9%
2024: 251.3%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Operating cash flow51.03.030153662.0287424304219219248289
Depreciation and amortization16.019.015.016.016.016.010.616.814.013.08.612.1
Capital expenditure-2.0-5.0-13.0-2.0-10.0-12.0-14.1-5.7-4.0-4.0-9.9-13.9
Investing cash flow2.0-9.0-5,572-54.026.0-43.0-60.333.5-1,270-210-65.5143
Financing cash flow-75.0-1775,229-21.0-406-13.0-21.5-41.3-440-85.0-3.32.8
Share repurchases-9.0-110-3.0-25.0-408-12.0-23.5-45.2-439-91.0-0.9-0.6
Debt issued——5,500—————————
Debt repaid-65.0-69.0-2.0-5.0-4.0-2.0-0.7-2.5-3.0-3.0-3.7-2.3
Effect of exchange rates4.0-11.0-4.04.0-5.08.017.64.5-14.0-1.0-91.147.4
Net change in cash-18.0-194-46.0465-323239359301-1,505-77.088.1482
Free cash flow49.0-2.028853452.0275410298215215238275
Levered free cash flow-67.433.6469364-104271278213200174193185